Target and Technology
SGN-CD123A is an antibody-drug conjugate (ADC) directed against CD123, a protein expressed across most acute myeloid leukemia (AML) subtypes, including on leukemic stem cells, which are difficult to kill and may be responsible for high rates of relapse even following intensive therapy. Normal hematopoietic stem cells are known to have limited expression of CD123. SGN-CD123A uses our proprietary ADC technology, where the anti-CD123 antibody is attached with a stable linker to two molecules of a highly potent DNA crosslinking agent called a pyrrolobenzodiazepine (PBD) dimer.
ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the cell killing power of potent cytotoxic agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.
Clinical Development Status
- Phase 1 trial evaluating safety and antitumor activity of SGN-CD123A in patients with AML
Proposed Mechanism of Action
SGN-CD123A is an investigational agent, and its safety and efficacy have not yet been established. ©2017 Seattle Genetics, Inc.